


AIM ImmunoTech Inc. (AIM)

NYSE; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0000946644

AIM ImmunoTech Inc. AIM; healthcare	
Grade	D  fourth fifth of 371 graded peers percentile 66.5; sampling error 2.5 points; lower is stronger
Rank	247 of 371
Profitability	A  percentile 10.1
Solvency	E  percentile 88.0
Growth and financing	C/D  percentile 61.7
Reliability	0.76 AUC filers with under \$12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under \$12.5M assets total assets \$5.8M
Standard universe	outside revenue above \$1M and assets above \$10M
Warnings	late filer, degenerate inputs, distress
Inputs computable	8 of 14
Graded from	filings received through Mar 27, 2026 196 days before the rescans; latest periodic filing 10-Q received Aug 7, 2026
Last close	\$0.18 2026-10-08; market equity \$5.5M
Price used in grade	None



D, the sloth
fourth fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: E from Apr 21, 2025, D from Apr 21, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 27, 2026

2026, we completed a rights offering to our stockholders and to holders of certain of our outstanding options and warrants that had the right to participate in the rights offering as of February 10, 2026, the record date. It raised approximately \$1,800,000 in gross proceeds. maintain our listing on the NYSE American (the "Exchange"), among other things, we are required to maintain Stockholders Equity of \$6,000,000 or we may receive a warning or a delisting notice.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 10.1						
Gross profitability		not computable	32.2%			latest aligned inputs end 2014-12-31; latest annual assets end 2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(41.7%)	(6.6%)	10.1	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 4
Solvency, sleeve percentile 88.0						
Twelve-month failure probability		3.37%	0.07%	93.9	248	2026-06-30
Altman Z double-prime		(266.06)	(0.31)	98.9	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		(14.36x)	(4.51x)	65.0	81	2025-12-31
Current ratio		0.53x	2.96x	94.0	839	2025-12-31
Growth and financing, sleeve percentile 61.7						
Revenue growth, three-year compound		(14.5%)	10.0%	87.0	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 13
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		(47.7%)	2.1%	98.0	704	2025-12-31
Net share issuance, one year		(88.7%)	2.5%	0.2	634	2026-03-25


Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 1 NT 10-K/Q filings in the last eight quarters
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor
Distress	CHS probability 3.371634%; universe top-decile threshold 1.068854%

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
242	Fulgent Genetics, Inc. (FLGT)	65.1	D	short runway
243	Entera Bio Ltd. (ENTX)	65.4	D	degenerate inputs
244	Dentsply Sirona Inc. (XRAY)	65.7	D	
245	InspireMD, Inc. (NSPR)	65.9	D	dilution, short runway, distress
246	Angiodynamics Inc. (ANGO)	66.2	D	fortress balance sheet
247	AIM ImmunoTech Inc. (AIM) <	66.5	D	late filer, degenerate inputs, distress
248	Exagen Inc. (XGN)	66.8	D	dilution, fortress balance sheet
249	PTC Therapeutics, Inc. (PTCT)	67.0	D	
250	Cardiff Oncology, Inc. (CRDF)	67.3	D	short runway, fortress balance sheet
251	Amylyx Pharmaceuticals, Inc. (AMLX)	67.6	D	short runway, degenerate inputs
252	U S Physical Therapy Inc. (USPH)	67.8	D	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(67.4%)	8.0%	7
Distance from 52-week high	(93.5%)	(31.4%)	3
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(272.6%)	(1.0%)	3
Book value to price	1.42	0.28	93
Sales to price	0.02	0.31	7
Composite equity issuance, five years	(182.6%)	20.3%	0
Relative strength against the sector, log excess return	(1.33)	(0.14)	7

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail

Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$9.9M
Operating cash flow, four quarters	-\$14.4M
Months of runway	8.3
Days since last periodic filing	63 (10-Q received Aug 7, 2026)
Median daily dollar volume, 63 sessions	\$242,065

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:Revenues	\$197,000	2014-12-31	2015-03-19	10-K	0000946644-15-000008
2	cost of revenue	us-gaap:CostOfRevenue	\$1.3M	2014-12-31	2015-03-19	10-K	0000946644-15-000008
3	assets	us-gaap:Assets	\$29.4M	2014-12-31	2016-03-29	10-K	0001615774-16-004671
4	net income	us-gaap:NetIncomeLoss	-\$14.0M	2025-12-31	2026-03-27	10-K	0001493152-26-013301
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$11.0M	2025-12-31	2026-03-27	10-K	0001493152-26-013301
6	assets	us-gaap:Assets	\$5.8M	2025-12-31	2026-03-27	10-K	0001493152-26-013301
7	assets	us-gaap:Assets	\$8.6M	2024-12-31	2026-03-27	10-K	0001493152-26-013301
8	current assets	us-gaap:AssetsCurrent	\$3.3M	2025-12-31	2026-03-27	10-K	0001493152-26-013301
9	current liabilities	us-gaap:LiabilitiesCurrent	\$6.2M	2025-12-31	2026-03-27	10-K	0001493152-26-013301
10	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$440.8M	2025-12-31	2026-03-27	10-K	0001493152-26-013301
11	operating income	us-gaap:OperatingIncomeLoss	-\$11.7M	2025-12-31	2026-03-27	10-K	0001493152-26-013301
12	book equity	us-gaap:StockholdersEquity	-\$9.8M	2025-12-31	2026-03-27	10-K	0001493152-26-013301
13	liabilities	us-gaap:Liabilities	\$15.6M	2025-12-31	2026-03-27	10-K	0001493152-26-013301
14	total debt	us-gaap:LongTermDebt	\$4.5M	2025-12-31	2026-03-27	10-K	0001493152-26-013301
15	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$3.0M	2025-12-31	2026-03-27	10-K	0001493152-26-013301
16	depreciation amortization	us-gaap:Depreciation	\$37,000	2025-12-31	2026-03-27	10-K	0001493152-26-013301
17	interest expense	us-gaap:InterestExpense	\$812,000	2025-12-31	2026-03-27	10-K	0001493152-26-013301
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$88,000	2025-12-31	2026-03-27	10-K	0001493152-26-013301
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$170,000	2024-12-31	2026-03-27	10-K	0001493152-26-013301
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$202,000	2023-12-31	2025-03-27	10-K	0001641172-25-000847
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$141,000	2022-12-31	2024-04-01	10-K	0001493152-24-012058
22	assets	us-gaap:Assets	\$19.4M	2023-12-31	2025-03-27	10-K	0001641172-25-000847
23	assets	us-gaap:Assets	\$40.5M	2022-12-31	2024-04-01	10-K	0001493152-24-012058
24	shares outstanding	dei:EntityCommonStockSharesOutstanding	8,147,782	2026-03-25	2026-03-27	10-K	0001493152-26-013301
25	shares outstanding	dei:EntityCommonStockSharesOutstanding	72,290,030	2025-03-24	2025-03-27	10-K	0001641172-25-000847